title: Influence of serum adiponectin level and SNP +45 polymorphism of adiponectin gene on myocardial fibrosis.
abstract: Adiponectin plays an important role in the development of hypertension, atherosclerosis, and cardiomyocyte hypertrophy, but very little was known about the influence of serum adiponectin or the adiponectin gene polymorphism on myocardial fibrosis. Our study investigates the influence of the SNP +45 polymorphism of the adiponectin gene and serum levels of adiponectin on myocardial fibrosis in patients with essential hypertension. A case-control study was conducted on 165 hypertensive patients and 126 normotensive healthy controls. The genotypes of adiponectin gene polymorphisms were detected by the polymerase chain reaction (PCR) method. Serum concentrations of procollagen were measured by a double antibody sandwich enzyme-linked immunosorbent assay (ELISA) in all subjects. The integrated backscatter score (IBS) was measured in the left ventricular myocardium using echocardiography. The serum levels of adiponectin in hypertensive patients were significantly lower than those in the normal control group ((2.69±1.0) μg/ml vs. (4.21±2.89) μg/ml, respectively, P<0.001). The serum levels of type-I procollagen carboxyl end peptide (PICP) and type-III procollagen ammonia cardinal extremity peptide (PIIINP) in the hypertension group were significantly higher than those in the control group. In the hypertension group, serum levels of adiponectin were significantly and negatively related to the average acoustic intensity and corrected acoustic intensity of the myocardium (r=0.46 and 0.61, respectively, P<0.05 for both). The serum levels of PICP and PIIINP were significantly different among the three genotypes of SNP +45 (P<0.01). Logistic regression analyses showed that sex and genotype (GG+GT) were the major risk factors of myocardial fibrosis in hypertensive patients (OR=5.343 and 3.278, respectively, P<0.05). These data suggest that lower levels of adiponectin and SNP +45 polymorphism of the adiponectin gene are likely to play an important role in myocardial fibrosis in hypertensive patients.
authors.affiliation: Department of Emergency, Jining First People's Hospital, Jining 272000, China.
authors.forename: Cheng-jun
authors.initials: CJ
authors.lastname: Yan
authors.forename: Su-mei
authors.initials: SM
authors.lastname: Li
authors.forename: Qiang
authors.initials: Q
authors.lastname: Xiao
authors.forename: Yan
authors.initials: Y
authors.lastname: Liu
authors.forename: Jian
authors.initials: J
authors.lastname: Hou
authors.forename: Ai-fang
authors.initials: AF
authors.lastname: Chen
authors.forename: Li-ping
authors.initials: LP
authors.lastname: Xia
authors.forename: Xiu-chang
authors.initials: XC
authors.lastname: Li
mesh_terms: D052242:Adiponectin / Q000097:blood* / Q000235:genetics*; D000328:Adult; D015415:Biomarkers / Q000097:blood; D016022:Case-Control Studies; D005260:Female; D005355:Fibrosis; D056726:Genetic Association Studies; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000235:genetics / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009206:Myocardium / Q000473:pathology*; D010446:Peptide Fragments / Q000097:blood; D020641:Polymorphism, Single Nucleotide; D011347:Procollagen / Q000097:blood; D012307:Risk Factors
chemical_list: C499918:ADIPOQ protein, human; D052242:Adiponectin; D015415:Biomarkers; D010446:Peptide Fragments; D011347:Procollagen; C041876:procollagen Type III-N-terminal peptide; C042813:procollagen type I carboxy terminal peptide
references.citation: Eur Heart J Cardiovasc Imaging. 2012 Jun;13(6):459-67
references.pmid: 22185752
references.citation: Cardiovasc Pathol. 2006 Mar-Apr;15(2):75-82
references.pmid: 16533695
references.citation: Clin Exp Hypertens. 2013;35(5):361-6
references.pmid: 23057719
references.citation: Blood Press. 2008;17(4):233-8
references.pmid: 18671144
references.citation: Atherosclerosis. 2011 Nov;219(1):322-9
references.pmid: 21813129
references.citation: J Clin Invest. 2006 Jul;116(7):1784-92
references.pmid: 16823476
references.citation: Circ J. 2008;72 Suppl A:A8-12
references.pmid: 18772529
references.citation: Crit Care. 2011 Apr 20;15(2):221
references.pmid: 21586104
references.citation: Diabetes. 2006 Jun;55(6):1723-30
references.pmid: 16731835
references.citation: J Cell Physiol. 2012 Feb;227(2):850-6
references.pmid: 21769867
references.citation: Nat Med. 2001 Aug;7(8):941-6
references.pmid: 11479627
references.citation: Am J Hypertens. 2012 Jul;25(7):746-55
references.pmid: 22534793
references.citation: Nat Clin Pract Cardiovasc Med. 2006 Jan;3(1):35-42
references.pmid: 16391616
references.citation: Circ J. 2009 Dec;73(12):2198-203
references.pmid: 19875896
references.citation: Scand J Clin Lab Invest. 2009;69(7):764-71
references.pmid: 19929719
references.citation: Cardiovasc Res. 2005 Sep 1;67(4):705-13
references.pmid: 15907819
references.citation: Eur J Endocrinol. 2009 Dec;161(6):845-52
references.pmid: 19755407
references.citation: Arterioscler Thromb Vasc Biol. 2008 May;28(5):863-70
references.pmid: 18309113
references.citation: Int J Obes (Lond). 2011 Dec;35(12):1487-94
references.pmid: 21364526
references.citation: ScientificWorldJournal. 2011 Jan 05;11:93-101
references.pmid: 21218266
references.citation: Hum Mol Genet. 2002 Oct 1;11(21):2607-14
references.pmid: 12354786
references.citation: Ultrasound Med Biol. 2004 Jul;30(7):885-91
references.pmid: 15313321
references.citation: Nat Rev Genet. 2002 Apr;3(4):285-98
references.pmid: 11967553
references.citation: Diabetes. 2002 Feb;51(2):536-40
references.pmid: 11812766
references.citation: Cardiovasc Res. 2011 Jul 1;91(1):116-23
references.pmid: 21354997
references.citation: Mol Biol Rep. 2012 May;39(5):5511-8
references.pmid: 22187345
references.citation: Circ Cardiovasc Imaging. 2011 Nov;4(6):693-702
references.pmid: 21946703
references.citation: J Hypertens. 2002 Jan;20(1):153-5
references.pmid: 11791039